Head-to-head evidence
Interferon beta-1b vs Rebif (interferon beta 1a)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanisms: Interferon beta receptor (type I IFN signaling) · Type I interferon receptor · full Multiple Sclerosis pipeline
Interferon beta-1b
Marketed by Bayer
NCT00099502 · Phase 3 · completed
The study was a large randomized, triple-blind, active-controlled trial comparing two interferon beta-1b doses with Copaxone, with relapse hazard as the clinical primary endpoint. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Rebif (interferon beta 1a)
Marketed by Merck KGaA and partners
NCT00110396 · Phase 3 · completed
The study was a single-group, open-label trial without randomization or a placebo or active comparator. Its primary endpoint was a laboratory antibody measure rather than a clinical outcome; 45 of 259 assessed participants were neutralising-antibody positive at week 96, but the design did not provide a controlled comparison.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Interferon beta-1b's landscape · Rebif (interferon beta 1a)'s landscape